Emasan AG

Emasan AG is a Swiss family office associated with the Sandoz family, focusing on strategic investments across various sectors and stages. The firm is known for its significant stake in Novartis AG, a global leader in pharmaceuticals and healthcare. In February 2025, Emasan AG sold a portion of its Novartis shares, realizing approximately 2.6 billion Swiss francs. This transaction underscores the firm's active role in managing and optimizing its investment portfolio. Emasan AG's investment philosophy emphasizes diversification and long-term value creation, reflecting the Sandoz family's commitment to sustainable growth and innovation. The firm's strategic approach involves identifying and supporting companies with strong growth potential, particularly in the healthcare and technology sectors, aligning with the family's legacy in the pharmaceutical industry. Through its investments, Emasan AG aims to contribute to advancements in healthcare and related industries, leveraging its expertise and resources to foster innovation and improve patient outcomes. The firm's activities are guided by a commitment to ethical investment practices and a focus on creating positive societal impact, consistent with the values upheld by the Sandoz family over generations.

Established companies with proven business models, Strong management teams, Potential for significant growth, Alignment with the Sandoz family's values and legacy